Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Biphenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279906 | 0.91 | KCNN4 (0.52) | KCNN4ALDH1A1KIF11TDP1HSD17B10 | |
| SCHEMBL18035826 | 0.76 | ALDH1A1 (0.44) | KCNN4ALDH1A1KIF11TDP1MAPK1 | |
| SCHEMBL874147 | 0.76 | KCNN4 (0.43) | KCNN4ALDH1A1KIF11TSHRALOX15 | |
| SCHEMBL23112981 | 0.76 | KCNN4 (0.43) | KCNN4ALDH1A1KIF11TDP1HSD17B10 | |
| SCHEMBL654702 | 0.72 | MAPK13 (0.42) | KCNN4ALDH1A1L3MBTL1LMNA | |
| SCHEMBL27675660 | 0.72 | KCNN4 (0.40) | KCNN4ALDH1A1KIF11TDP1HSD17B10 | |
| SCHEMBL7535593 | 0.71 | KCNN4 (0.39) | KCNN4ALDH1A1KIF11TDP1HSD17B10 | |
| SCHEMBL9479803 | 0.71 | NPC1 (0.49) | ALDH1A1KIF11L3MBTL1CYP2C9LMNA | |
| SCHEMBL11043879 | 0.70 | KCNN4 (0.46) | KCNN4ALDH1A1TDP1HSD17B10CTSD | |
| SCHEMBL6929062 | 0.70 | ALDH1A1 (0.43) | KCNN4ALDH1A1TDP1HSD17B10CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020057050-A1 | Organic light emitting diode devices using aromatic amine compounds with high and tunable glass transition temperatures | EMAGIN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| WO-2002001653-A2 | ORGANIC LIGHT EMITTING DIODE DEVICES USING AROMATIC AMINE COMPOUNDS WITH HIGH AND TUNABLE GLASS TRANSITION TEMPERATURES | EMAGIN CORPORATION (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020057050-A1 | Organic light emitting diode devices using aromatic amine compounds with high and tunable glass transition temperatures | DRD4, DRD2, DRD1 | SLC6A2 57/4885KCNN4 515/4885ALDH1A1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.